Hybrid Drug Targets Epigenetic Changes in Melanoma Cells

Actively targeting specific genetic mutations that give rise to cancer is challenging enough for researchers and drug manufacturers, but trying to target changes that arise due to differential expression and regulation of gene products takes the concept of challenging to a new level. Yet, that is exactly what a team of researchers from Boston University School of Medicine, Johns Hopkins University, Universit à di Pavia, Harvard Medical School, and the University of Leicester has just acco